Lv1
60 积分 2023-06-17 加入
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial
1个月前
已完结
Reply to: The Role of Risk-Reducing Bilateral Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers
1个月前
已关闭
Menopausal Hormone Therapy After Breast Cancer: Personalization, Not Prohibition
3个月前
已关闭
Carboplatin for Patients With Triple-Negative Breast Cancer
3个月前
已关闭
Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial
3个月前
已关闭
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression
5个月前
已完结
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression
5个月前
已完结
皖公网安备34019202002308
